A moment worth remembering: what SCALE tells us about the future of aesthetics 

Olivia Brown, EVP, Head of Neuroscience 

There are moments that stay with you. Not because of a single slide or headline, but because you can feel something changing. Expectations shift. Standards rise. A new chapter begins. 

That is what SCALE represented this year: it signalled the directions where aesthetic medicines is heading. Aesthetic medicine is evolving beyond surface‑level outcomes. Physicians increasingly seek treatments grounded in evidence, developed with intention, and delivered to consistently high standards.  

For Ipsen, this moment also matters. We are not new to aesthetics. For decades, our development in neuroscience has spanned both therapeutic and aesthetic indications, supported by deep experience in complex biologics and high‑quality manufacturing. Our medicines are approved for aesthetic use in more than 80 countries worldwide, through our direct presence and trusted partners. 

What differentiates companies in this field is their approach and execution. 

Aesthetics addresses individual patient needs. Behind every treatment decision is a human story: a change in life, confidence, identity, or sense of self. People are looking for a quality of life, not solely an aesthetic enhancement.  

That is why the future of aesthetics will be shaped by a more intentional standard, one that respects the individual, values consistency and predictability, and recognizes the responsibility that comes with developing, manufacturing and delivering these treatments. 

At Ipsen, we follow the science and let data guide our decisions. This principle extends beyond research. It means refusing shortcuts, designing with purpose and committing to quality at every step – from development through to manufacturing. 

SCALE marked that shift. Not just a congress, but a point in time that reflects the direction the aesthetics industry is taking and the standards the community expects. It was also a milestone for Ipsen, as our role in aesthetics became more visible.  

For me personally, this moment carries added significance. Since joining Ipsen I found a sharper awareness of the moments that shape not just careers, but responsibility for the standards we set and the trust we earn. SCALE was one of those moments. 

A reminder that aesthetics is entering a more considered, more intentional era – one where scientific rigour, quality and standards matter as much as outcomes. And one where how we innovate is just as important as what we create.